Merdury Biopharmaceutical Corporation(TW:6932)
NT$5.23-0.26 (-4.74%)
TW:6932
Merdury Biopharmaceutical Corporation financials statements
NT$5.23
At close:-0.26 (-4.74%)
Merdury Biopharmaceutical Corporation (6932) Ratios
Merdury Biopharmaceutical Corporation Ratios
TW:6932's free cash flow for Q2 2026 was NT$-28.93M. For the 2026 fiscal year, TW:6932's free cash flow was decreased by NT$-6.79M and operating cash flow was NT$-22.14M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 8.84 | 12.63 | 42.21 | 20.15 | 2.30 |
| Quick Ratio | 8.84 | 12.63 | 42.21 | 20.15 | 2.30 |
| Cash Ratio | 2.69 | 3.54 | 5.50 | 4.42 | 1.50 |
| Solvency Ratio | -0.95 | -0.69 | -0.80 | -0.57 | -1.48 |
| Operating Cash Flow Ratio | -2.57 | -1.80 | -5.23 | -3.57 | -2.81 |
| Short-Term Operating Cash Flow Coverage | -24.03 | -28.59 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | NT$ 116.04M | NT$ 179.97M | NT$ 290.21M | NT$ 96.13M | NT$ 1.00M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.15 | 0.13 | 0.10 | 0.19 | 0.15 |
| Debt-to-Equity Ratio | 0.19 | 0.16 | 0.11 | 0.24 | 0.19 |
| Debt-to-Capital Ratio | 0.16 | 0.14 | 0.10 | 0.19 | 0.16 |
| Long-Term Debt-to-Capital Ratio | 0.15 | 0.12 | 0.10 | 0.19 | 0.00 |
| Financial Leverage Ratio | 1.27 | 1.22 | 1.13 | 1.28 | 1.28 |
| Debt Service Coverage Ratio | -18.90 | -21.00 | -54.90 | -70.26 | -393.27 |
| Interest Coverage Ratio | -76.33 | -67.47 | -64.26 | -77.13 | -481.64 |
| Debt to Market Cap | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 |
| Interest Debt Per Share | 0.10 | 0.12 | 0.11 | 0.12 | 0.01 |
| Net Debt to EBITDA | 0.20 | 0.48 | 0.05 | -0.41 | 0.13 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 84.30% | 57.31% | 43.73% | 0.00% |
| EBIT Margin | 0.00% | -1001.95% | -4172.80% | -1151.12% | 0.00% |
| EBITDA Margin | 0.00% | -851.78% | -3778.70% | -1048.62% | 0.00% |
| Operating Profit Margin | 0.00% | -1088.90% | -4423.04% | -1151.12% | 0.00% |
| Pretax Profit Margin | 0.00% | -1018.09% | -4241.63% | -1166.04% | 0.00% |
| Net Profit Margin | 0.00% | -1018.90% | -4241.63% | -1166.04% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | -1018.90% | -4241.63% | -1166.04% | 0.00% |
| Net Income Per EBT | 100.09% | 100.08% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 97.99% | 93.50% | 95.90% | 101.30% | 100.21% |
| Return on Assets (ROA) | -24.15% | -14.32% | -10.00% | -13.59% | -39.68% |
| Return on Equity (ROE) | -30.61% | -17.42% | -11.28% | -17.33% | -50.77% |
| Return on Capital Employed (ROCE) | -26.50% | -16.18% | -10.63% | -13.85% | -45.37% |
| Return on Invested Capital (ROIC) | -26.22% | -16.00% | -10.61% | -13.79% | -42.50% |
| Return on Tangible Assets | -24.63% | -14.50% | -10.06% | -13.62% | -41.17% |
| Earnings Yield | -1.93% | -0.93% | -0.60% | -0.83% | -0.16% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 992.60 | 44.91 | 116.52 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.05 | 0.01 | 0.04 | 0.00 |
| Asset Turnover | 0.00 | 0.01 | 0.00 | 0.01 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.02 | 0.00 | 0.04 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.37 | 8.13 | 3.13 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.37 | 8.13 | 3.13 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.37 | 8.13 | 3.13 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.12 | -0.08 | -0.11 | -0.07 | -0.02 |
| Free Cash Flow Per Share | -0.14 | -0.11 | -0.14 | -0.25 | -0.04 |
| Dividend Paid and CapEx Coverage Ratio | -6.97 | -3.13 | -3.11 | -0.38 | -0.64 |
| Capital Expenditure Coverage Ratio | -6.97 | -3.13 | -3.11 | -0.38 | -0.64 |
| Operating Cash Flow Coverage Ratio | -1.22 | -0.73 | -1.00 | -0.60 | -2.38 |
| Operating Cash Flow to Sales Ratio | 0.00 | -6.99 | -40.80 | -9.64 | 0.00 |
| Free Cash Flow Yield | -1.67% | -0.84% | -0.76% | -2.51% | -0.37% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -51.88 | -108.75 | -166.82 | -120.48 | -627.23 |
| Price-to-Sales (P/S) Ratio | 0.00 | 1093.81 | 7075.80 | 1404.71 | 0.00 |
| Price-to-Book (P/B) Ratio | 15.88 | 18.70 | 18.82 | 20.88 | 318.87 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -59.99 | -118.50 | -131.19 | -39.84 | -271.19 |
| Price-to-Operating Cash Flow Ratio | -68.60 | -156.40 | -173.43 | -145.68 | -697.06 |
| Price-to-Earnings Growth (PEG) Ratio | -1.56 | -11.96 | -5.00 | -0.36 | -0.24 |
| Enterprise Value Multiple | -61.08 | -127.93 | -187.21 | -134.37 | -770.57 |
| Enterprise Value | 3.48B | 5.41B | 7.31B | 3.78B | 3.33B |
| EV to EBITDA | -61.08 | -127.93 | -187.21 | -134.37 | -770.57 |
| EV to Sales | 0.00 | 1089.68 | 7073.92 | 1409.00 | 0.00 |
| EV to Free Cash Flow | -59.79 | -118.06 | -131.15 | -39.96 | -271.15 |
| EV to Operating Cash Flow | -68.38 | -155.81 | -173.39 | -146.12 | -696.95 |
| Tangible Book Value Per Share | 0.51 | 0.69 | 0.97 | 0.47 | 0.04 |
| Shareholders’ Equity Per Share | 0.52 | 0.70 | 0.97 | 0.48 | 0.04 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.00 | -0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.01 | 0.00 | 0.01 | 0.00 |
| Net Income Per Share | -0.16 | -0.12 | -0.11 | -0.08 | -0.02 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 0.98 | 1.02 | 1.02 | 1.01 | 1.00 |
| Research & Development to Revenue | 0.00 | 6.58 | 20.69 | 5.75 | 0.00 |
| SG&A to Revenue | 0.00 | 5.15 | 24.12 | 6.22 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.25 | 1.76 | 0.42 | 0.00 |
| Income Quality | 0.76 | 0.69 | 0.96 | 0.83 | 0.90 |
Currency in TWD
